Viridian Therapeutics partners with Kissei Pharmaceutical to advance treatments for thyroid eye disease in Japan, enhancing patient care and market potential.

Companies have scant financial incentive to develop new antibiotics. Will the NIH continue to support relevant research?

The National Institute for Pharmaceutical Research and Development (NIPRD) has announced the imminent commencement of the €18 million European Union ...

Dr. Falk Pharma, in cooperation with its fully-owned subsidiary Losan Pharma GmbH, a leading contract development and ...

Bon Natural Life Limited (Nasdaq: BON) ('BON' or 'the Company'), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

In an exclusive interview with Business Today, D. Sridhar Babu, Minister for Information Technology, Industries and Commerce, ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Astellas Pharma has entered a memorandum of understanding (MoU) with the Korea Institute of Startup and Entrepreneurship Development (KISED).

Lived experience with suicide significantly affected how pharmacists supported at-risk patients and could be used to improve ...

As leaders across the United States consider options to reduce healthcare costs, they must ensure that well-intended reforms ...

Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts ...